Radiotherapy · Theranostics · Prostate Cancer
Actinium Pharmaceuticals Hosts Webinar on ATNM-400 for mCRPC
November 16, 2026 · News Release
Source: Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has announced a webinar featuring expert Michael J. Morris, MD, from Memorial Sloan Kettering Cancer Center, scheduled for December 1, 2026, at 8:00 a.m. ET. The focus will be on the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) and the investigational agent ATNM-400, a first-in-class HER3-targeted Actinium-225 antibody radioconjugate.
The discussion will explore ATNM-400's applicability for mCRPC patients, particularly those with low or negative PSMA expression, and will address the challenges faced by patients who do not respond to or progress after PSMA-directed therapies. Key topics will include the role of HER3 in tumor progression and treatment resistance, the rationale for alpha radiotherapy targeting HER3, and the need for alternatives outside of PSMA-targeted therapies.
Morris and the team will review findings from the ongoing first-in-human Phase 1 HERACT-PRO-1 trial for ATNM-400. Initial results presented at the 2026 European Association of Nuclear Medicine Congress indicated HER3-targeted PET imaging showed tumor uptake and retention through Day 7, with no dose-limiting toxicities or significant adverse events in the three-patient cohort at the 1.0 µCi/kg dose level. Dose escalation has progressed to 1.5 µCi/kg and continues.
The RADIANZ imaging study, aimed at validating the pan-tumor potential of ATNM-400, will also be discussed. This study utilizes PET imaging with Zirconium-89-labeled barecetamab to evaluate tumor targeting and biodistribution.
A live question-and-answer session will be included after the presentations.
Webinar Details
Date: December 1, 2026
Time: 8:00 a.m. Eastern Time
Registration: Available through Actinium's website.
ATNM-400 combines the specificity of a HER3-targeting monoclonal antibody with the isotope Actinium-225, offering the potential for focused alpha radiation therapy. Its unique approach sets it apart from existing PSMA-targeted therapies and allows for broader applications in cancers that express HER3, including lung, breast, colorectal, and ovarian cancers.
For more information on Actinium Pharmaceuticals and its developments, please visit Actinium's website.

